Unless corrected, the Federal Circuit’s ruling in GSK v. Teva widely threatens the ability of generic and biosimilar developers to deliver more affordable medicines to patients in as timely a manner as possible.
Unless corrected, the Federal Circuit’s ruling in GSK v. Teva widely threatens the ability of generic and biosimilar developers to deliver more affordable medicines to patients in as timely a manner as possible.
